CytOSorb TreatMent Of Critically Ill PatientS Registry (COSMOS)

CytoSorbents

Status: Enrolling

Conditions: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS); Postoperative Endocarditis; Acute Liver Failure; Rhabdomyolysis; Liver Transplant; Complications; Trauma; Postoperative Vasoplegic Syndrome; Pancreatitis; Acute Respiratory Distress Syndrome; Infectious Disease; Sepsis; Acute on Chronic Liver Failure; Extracorporeal Life Support; Hemophagocytic Lymphohistiocytoses; Burns; Cardiogenic Shock; Septic Shock; Drug Overdose

Treatments: Device: CytoSorb

Study type: Observational

Funder types: Industry

Identifiers

NCT05146336

O06

Details and patient eligibility

About

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Enrollment: 3,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Planned OR actual CytoSorb® 300 mL device utilization
2. Informed consent for prospective registry participation

Exclusion criteria

1. Use of the CytoSorb® 300 mL device for antithrombotic removal only
2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.